Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$483.00 USD

483.00
2,259,829

-15.73 (-3.15%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should Value Investors Pick Vertex Pharmaceuticals (VRTX) Stock?

by Zacks Equity Research

Let's see if Vertex Pharmaceuticals Incorporated (VRTX) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Agios (AGIO) Gets FDA Nod for Rare Anemia Drug Mitapivat

by Zacks Equity Research

Agios Pharmaceuticals' (AGIO) Pyrukynd (mitapivat) is the first disease-modifying therapy approved to treat PK deficiency, a rare, debilitating, blood disorder.

Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Repligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022.

Sage Therapeutics (SAGE) Depression Drug Meets Goal, Stock Down

by Zacks Equity Research

Sage Therapeutics (SAGE) and Biogen's (BIIB) depression candidate, zuranolone given along with antidepressants improves depressive symptoms in a phase III study. Questions remain about the durability of the drug.

AstraZeneca's (AZN) Lupus Drug Saphnelo Gets Europe Nod

by Zacks Equity Research

AstraZeneca's (AZN) Saphnelo is the only new biologic to be approved in Europe in over a decade for patients with systemic lupus erythematosus.

Intellia (NTLA) Up on Deal With ONK for Cancer Therapies

by Zacks Equity Research

Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.

CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/Y

by Zacks Equity Research

CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis' (ZTS) earnings and revenues beat estimates for the fourth quarter of 2021.

VRTX vs. TECH: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

VRTX vs. TECH: Which Stock Is the Better Value Option?

BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium

by Zacks Equity Research

Collegium (COLL) is set to acquire BioDelivery (BDSI) for approximately $604 million in cash. The transaction is likely to be completed by the end of first-quarter 2022.

Will Dynavax's (DVAX) Growth Momentum Continue in 2022?

by Zacks Equity Research

Year-over-year revenue growth for HEPLISAV-B and CpG 1018 adjuvant is expected to drive Dynavax???s (DVAX) profitability in 2022.

ProQR (PRQR) Plunges as Lead Drug Fails in Phase II/III Study

by Zacks Equity Research

ProQR (PRQR) lead candidate sepofarsen did not meet primary and secondary goals in phase II/III study.

Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA

by Zacks Equity Research

Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.

Zacks Industry Outlook Highlights: Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals

by Zacks Equity Research

Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals are highlighted in this Industry Outlook article.

Alnylam's (ALNY) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Alnylam's (ALNY) earnings fall shy of estimates in the fourth quarter of 2021 while revenues beat the same. The company issues 2022 guidance for net product revenues.

CureVac (CVAC) Begins Influenza Shot Dosing in Phase I Study

by Zacks Equity Research

CureVac (CVAC) doses the first patient in a phase I study with investigational influenza vaccine candidate.

Lilly (LLY) Gets FDA Panel Advice for New Study on Sintilimab

by Zacks Equity Research

An FDA advisory for Lilly's (LLY) partner Innovent Biologics calls for conducting a new study on its first-line lung cancer candidate, sintilimab, for gaining approval for the same in the United States.

Will the Rally of These 5 Big Drugmakers Continue in 2022?

by Zacks Equity Research

Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals.

Seagen (SGEN) Q4 Earnings Miss, Revenues Top Mark, Stock Down

by Zacks Equity Research

Seagen (SGEN) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock falls in after-hours trading.

TEVA Stock Up on Q4 Earnings Beat, Sales Miss Estimates

by Zacks Equity Research

Shares of TEVA rise 8.4% after the company beat earnings estimates despite missing on sales for fourth-quarter 2021. It issues its financial guidance for 2022.

Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA

by Zacks Equity Research

Regeneron (REGN) and Sanofi get Priority Review for their sBLA in the United States seeking label expansion of Dupixent.

Is GlaxoSmithKline (GSK) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how GlaxoSmithKline (GSK) and Vertex Pharmaceuticals (VRTX) have performed compared to their sector so far this year.

CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On CRISPR Therapeutics' (CRSP) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates, especially its lead candidate CTX001.

Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Bristol-Myers (BMY) Q4 Earnings Meet Estimates, Sales Beat

by Zacks Equity Research

Bristol-Myers (BMY) earnings match estimates in the fourth quarter of 2021, while sales beat the same on the back of Eliquis and Opdivo.